Metformin Associated With Increased Survival in Type 2 Diabetes Patients With Pancreatic Cancer and Lymphoma
- 4 July 2019
- journal article
- research article
- Published by Elsevier BV in The American Journal of the Medical Sciences
- Vol. 358 (3), 200-203
- https://doi.org/10.1016/j.amjms.2019.06.002
Abstract
No abstract availableKeywords
Funding Information
- NIH (DK-113964-02)
This publication has 22 references indexed in Scilit:
- Cancer and diabetes: are we ready for prime time?Diabetologia, 2010
- TNF-α Inhibits Insulin Action in Liver and Adipose Tissue: A Model of Metabolic SyndromeHormone and Metabolic Research, 2009
- LKB1 and Mammalian Target of Rapamycin As Predictive Factors for the Anticancer Efficacy of MetforminJournal of Clinical Oncology, 2009
- Diabetes and cancerEndocrine-Related Cancer, 2009
- Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, aurorasandpolo-like kinases] M-phase cell cycle genes in human breast cancer cellsCell Cycle, 2009
- The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 levelOncogene, 2008
- The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic inventionMolecular Cancer, 2007
- Phosphoinositide 3-kinase regulatory subunit p85α suppresses insulin action via positive regulation of PTENProceedings of the National Academy of Sciences of the United States of America, 2006
- Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US AdultsAmerican Journal of Epidemiology, 2004
- The PTEN Tumor Suppressor Protein Inhibits Tumor Necrosis Factor-induced Nuclear Factor κB ActivityOnline Journal of Public Health Informatics, 2001